agitation associated with dementia of the Alzheimer’s type.
– Subjects with a diagnosis of probable Alzheimer’s disease.
– Subjects with a diagnosis of agitation
– Subjects with a MMSE score of 5 to 22, inclusive, at screening and baseline visits.
– Subjects with a previous MRI or CT scan of the brain, that was performed after the
onset of symptoms of dementia, with findings consistent with a diagnosis of
– Subjects who are residing at their current location for at least 28 days before
screening and are expected to remain at the same location for the duration of the
– Institutionalized subjects with an identified caregiver who has sufficient contact
(minimum of 2 hours per day for 4 days per week) to describe the subject’s symptoms
and has direct observation of the subject’s behavior. Non-institutionalized subjects
may not be living alone and must have an identified caregiver who has sufficient
contact (minimum of 2 hours per day for 4 days per week) to describe the subject’s
symptoms and has direct observation of the subject’s behavior.
– Subjects with onset of symptoms of agitation at least 2 weeks prior to screening
– Subjects will and able to discontinue all prohibited concomitant medications to meet
protocol required washouts prior to and during the trial period.
– Subjects with dementia or other memory impairment not due to Alzheimer’s disease.
– Subjects with a history of stroke, well-documented transient ischemic attack, or
pulmonary or cerebral embolism.
– Subjects who had an insufficient response, based on the investigator’s judgment, to 2
or more previous antipsychotic medications.
– Subjects who have been diagnosed with an Axis I disorder.
– Subjects who currently have clinically significant neurological, hepatic, renal,
metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal,
or psychiatric disorders.
– Subjects with uncontrolled hypertension or symptomatic hypotension, or orthostatic
– Subjects with diabetes mellitus (insulin-dependent and non-insulin-dependent) may be
eligible for the trial if their condition is stable and well-controlled.
- For additional information regarding sites, contact 844-687-8522, Los Angeles, California, United States, 90036